SEGMENT 1 — INTRO / LEAD STORY

Good morning. It's Sunday, September 6th, and there's a genuine milestone worth covering in sleep medicine this weekend. For the first time, the FDA is formally reviewing a prescription pill designed to treat obstructive sleep apnea. The drug is called AD109, developed by a small biotech company called Apnimed. The FDA accepted their New Drug Application in July, meaning it's now under active review. If AD109 clears — and a decision could come as early as the first quarter of 2027 — it would be the first oral medication ever approved specifically for OSA.

Let's put that in perspective. Sleep apnea has been treated almost exclusively with mechanical solutions since CPAP therapy was introduced in the early 1980s. Oral appliances and surgery exist as alternatives, but a once-nightly pill that directly targets the airway muscle dynamics that cause apnea events is a genuinely new category.

SEGMENT 2 — AD109 WHAT IT MEANS

In Phase 3 clinical trials, AD109 cut apnea events per hour by about 44 percent. That's meaningful, but it's worth comparing to CPAP. When patients use CPAP consistently, most see a 90 percent or greater reduction in apnea events. So AD109 is not positioned to replace CPAP for most patients — and it shouldn't be. It's aimed at the large group of people who cannot tolerate CPAP or won't stick with it long-term.

That group is enormous. Research consistently shows that somewhere between 70 and 80 percent of people with clinically significant sleep apnea in the U.S. are either undiagnosed or untreated. A pill that can bring even a fraction of those people into treatment — and then connect them with a testing and resupply pathway — represents a real shift in the pipeline. For programs like Heartstrong Sleep, the downstream implication is that more patients may be entering care through a new front door. Whether they eventually transition to or add CPAP therapy depends on severity and tolerance, but diagnosis and engagement is the starting point for everything else.

SEGMENT 3 — RESMED ERS CONGRESS DATA

Now to Barcelona. ResMed is presenting research this week at the European Respiratory Society Congress, which runs September 5th through the 9th. One finding from their dataset is worth highlighting. The data shows that each additional hour of nightly PAP therapy use is associated with a statistically measurable reduction in mortality risk among people with obstructive sleep apnea.

This builds on a body of prior research, but what ResMed is adding is real-world usage data from their connected device network — which covers tens of millions of active patients globally. That scale matters. It's not a controlled trial with a small cohort; it's observational data from an enormous, real-world population. The direction of the finding is consistent: more nightly use, better outcomes. And the dose-response relationship — where each additional hour contributes to the benefit — gives clinicians a concrete message for patients who are using their device for 3 hours a night and wondering if it's worth the effort. The answer from this data is yes, and more is better.

For resupply and adherence teams, this data is a clinical anchor. When a patient calls because their mask is uncomfortable or they're thinking about stopping therapy, the conversation isn't just about compliance metrics or insurance coverage windows. It's about survival benefit — framed in plain language.

SEGMENT 4 — MARKET OUTLOOK

Stepping back to the broader market picture. MarketsandMarkets estimates the U.S. sleep apnea devices market at approximately 3.1 billion dollars in 2026, with a forecast of 4.5 billion by 2031. That's roughly 8 percent compound annual growth over five years, driven by rising diagnosis rates, expanded home sleep testing, and growing employer and insurer focus on sleep health as a preventive care priority.

For a resupply-focused business like Heartstrong Sleep, that trajectory points to a steadily growing patient population over the next several years. The competitive question is which providers build the strongest patient relationships at diagnosis — and sustain them through the full therapy journey.